BACKGROUND: Alzheimer's disease (AD) and prion diseases such as sporadic Creutzfeldt-Jakob disease (sCJD) share common features concerning their molecular pathogenesis and neuropathological presentation and the coexistence of AD and CJD in patients suggest an association between the deposition of the proteolytically processed form of the amyloid precursor protein, beta-amyloid (Abeta), which deposits in AD, and the abnormal form of the prion protein, PrP(Sc), which deposits in sCJD. METHODS: We have characterized sCJD patients (n = 14), AD patients (n = 5) and nondemented controls (n = 5) with respect to the deposition of PrP(Sc) and Abeta morphologically, biochemically and genetically and correlated these findings to clinical data. RESULTS: sCJD-diseased individuals with abundant deposits of Abeta present with a specific clinicopathological profile, defined by higher age at disease onset, long disease duration, a genetic profile and only minimal amounts of PrP(Sc) in the cerebellum. CONCLUSION: The co-occurrence of pathological changes typical for sCJD and AD in combination with the inverse association between accumulation of Abeta and PrP(Sc) in a subgroup of sCJD patients is indicative of common pathways involved in the generation or clearance of Abeta and PrP(Sc) in a subgroup of sCJD patients. Copyright 2008 S. Karger AG, Basel.
BACKGROUND:Alzheimer's disease (AD) and prion diseases such as sporadic Creutzfeldt-Jakob disease (sCJD) share common features concerning their molecular pathogenesis and neuropathological presentation and the coexistence of AD and CJD in patients suggest an association between the deposition of the proteolytically processed form of the amyloid precursor protein, beta-amyloid (Abeta), which deposits in AD, and the abnormal form of the prion protein, PrP(Sc), which deposits in sCJD. METHODS: We have characterized sCJD patients (n = 14), ADpatients (n = 5) and nondemented controls (n = 5) with respect to the deposition of PrP(Sc) and Abeta morphologically, biochemically and genetically and correlated these findings to clinical data. RESULTS: sCJD-diseased individuals with abundant deposits of Abeta present with a specific clinicopathological profile, defined by higher age at disease onset, long disease duration, a genetic profile and only minimal amounts of PrP(Sc) in the cerebellum. CONCLUSION: The co-occurrence of pathological changes typical for sCJD and AD in combination with the inverse association between accumulation of Abeta and PrP(Sc) in a subgroup of sCJD patients is indicative of common pathways involved in the generation or clearance of Abeta and PrP(Sc) in a subgroup of sCJD patients. Copyright 2008 S. Karger AG, Basel.
Authors: Olga Calero; María J Bullido; Jordi Clarimón; Rafael Hortigüela; Ana Frank-García; Pablo Martínez-Martín; Alberto Lleó; María Jesús Rey; Isabel Sastre; Alberto Rábano; Jesús de Pedro-Cuesta; Isidro Ferrer; Miguel Calero Journal: Prion Date: 2012-08-09 Impact factor: 3.931
Authors: Nupur Ghoshal; Ignazio Cali; Richard Justin Perrin; S Andrew Josephson; Ning Sun; Pierluigi Gambetti; John Carl Morris Journal: Arch Neurol Date: 2009-10
Authors: Megan Larson; Mathew A Sherman; Fatou Amar; Mario Nuvolone; Julie A Schneider; David A Bennett; Adriano Aguzzi; Sylvain E Lesné Journal: J Neurosci Date: 2012-11-21 Impact factor: 6.167
Authors: Olga Calero; María J Bullido; Jordi Clarimón; Ana Frank-García; Pablo Martínez-Martín; Alberto Lleó; María Jesús Rey; Isabel Sastre; Alberto Rábano; Jesús de Pedro-Cuesta; Isidro Ferrer; Miguel Calero Journal: PLoS One Date: 2012-08-30 Impact factor: 3.240